EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Can Incorporating Molecular Testing Improve the Accuracy of Newborn Screening for Congenital Adrenal Hyperplasia?

Kyriakie Sarafoglou iD, Amy Gaviglio, Carrie Wolf, Cindy P Lorentz, Aida Lteif, Jennifer Kyllo, Gretchen Radloff, Zachary Detwiler, Carla D Cuthbert, James S Hodges, Scott D Grosse, Christopher N Greene und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 17.03.2025 · 110 (4) · e1194-e1203

DOI: 10.1210/clinem/dgae297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 03.05.2024. Verfasst von Kyriakie Sarafoglou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55454, USA. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Neonatal Screening, Steroid 21-Hydroxylase, Genetic Testing. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural CDC HHS, March of Dimes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Single-tier newborn screening (NBS) for congenital adrenal hyperplasia (CAH) using 17-hydroxyprogesterone (17OHP) measured by fluoroimmunoassay (FIA) in samples collected at 24 to 48 hours produces a high false-positive rate (FPR). Second-tier steroid testing can reduce the FPR and has been widely implemented.

Objective

We investigated the accuracy of an alternative multitier CAH NBS protocol that incorporates molecular testing of the CYP21A2 gene and reduces the first-tier 17OHP cutoff to minimize missed cases.

Methods

We create a Minnesota-specific CYP21A2 pathogenic variants panel; developed a rapid, high-throughput multiplex, allele-specific-primer-extension assay; and performed a 1-year retrospective analysis of Minnesota NBS results comparing metrics between a conventional steroid-based 2-tier protocol and a molecular-based multitier NBS protocol, applied post hoc.

Results

CYP21A2 gene sequencing of 103 Minnesota families resulted in a Minnesota-specific panel of 21 pathogenic variants. The Centers for Disease Control and Prevention created a molecular assay with 100% accuracy and reproducibility. Two-tier steroid-based screening of 68 659 live births during 2015 resulted in 2 false negatives (FNs), 91 FPs, and 1 true positive (TP). A 3-tier protocol with a lower first-tier steroid cutoff, second-tier 21-variant CYP21A2 panel, and third-tier CYP21A2 sequencing would have resulted in 0 FNs, 52 FPs, and 3 TPs.

Conclusion

Incorporation of molecular testing could improve the accuracy of CAH NBS, although some distinct challenges of molecular testing may need to be considered before implementation by NBS programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalNeonatal ScreeningSteroid 21-HydroxylaseGenetic TestingHumansInfant, NewbornRetrospective Studies17-alpha-HydroxyprogesteroneFemaleMaleFalse Positive ReactionsFluoroimmunoassayMinnesotaReproducibility of Results

Stichwörter der Autor:innen

CYP21A2 genecongenital adrenal hyperplasianewborn screeningpremature infants

Substanzen

Steroid 21-HydroxylaseCYP21A2 protein, human17-alpha-Hydroxyprogesterone

Autor:innen und Institutionen

  • Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55454, USA.
  • Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA.
  • Newborn Screening Program, Minnesota Department of Health, St. Paul, MN 55155, USA.
  • 4ES Corporation, San Antonio, TX 78261, USA.
  • Department of Pediatrics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
  • Department of Endocrinology, Children's Hospitals and Clinics of Minnesota, St. Paul, MN 55102, USA.

ORCID-Profile: Kyriakie Sarafoglou

Förderung

  • Intramural CDC HHS
  • March of Dimes

Zitieren

APA

Sarafoglou, K., Gaviglio, A., Wolf, C., Lorentz, C. P., Lteif, A., Kyllo, J., Radloff, G., Detwiler, Z., Cuthbert, C. D., Hodges, J. S., Grosse, S. D., Greene, C. N., & Cordovado, S. (2025). Can Incorporating Molecular Testing Improve the Accuracy of Newborn Screening for Congenital Adrenal Hyperplasia?. The Journal of Clinical Endocrinology & Metabolism, 110(4), e1194-e1203. https://doi.org/10.1210/clinem/dgae297

Vancouver

Sarafoglou K, Gaviglio A, Wolf C, Lorentz CP, Lteif A, Kyllo J, et al. Can Incorporating Molecular Testing Improve the Accuracy of Newborn Screening for Congenital Adrenal Hyperplasia?. The Journal of Clinical Endocrinology & Metabolism. 2025;110(4):e1194-e1203. doi:10.1210/clinem/dgae297

BibTeX
@article{Sarafoglou2025,
  author = {Sarafoglou, Kyriakie and Gaviglio, Amy and Wolf, Carrie and Lorentz, Cindy P and Lteif, Aida and Kyllo, Jennifer and Radloff, Gretchen and Detwiler, Zachary and Cuthbert, Carla D and Hodges, James S and Grosse, Scott D and Greene, Christopher N and Cordovado, Suzanne},
  title = {Can Incorporating Molecular Testing Improve the Accuracy of Newborn Screening for Congenital Adrenal Hyperplasia?},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {4},
  pages = {e1194--e1203},
  doi = {10.1210/clinem/dgae297}
}
Kostenlos starten →